The Recall Desk
CriticalFDA (Drugs)·D-1309-2019·Announced 2019-05-29

Novartis Recalls Promacta Oral Suspension Due to Peanut Cross-Contamination

Novartis is recalling Promacta (eltrombopag olamine) 12.5 mg oral suspension due to possible cross-contamination with peanut flour.

What this means for you

Highest-severity recall. Risk of serious injury or death is documented or strongly suspected. Stop using the product now and follow the agency's instructions.

Our severity reasoning: The FDA has classified this recall as Class I, which meets the rubric criteria for a Critical severity score (5).

Plain-English summary

Novartis Pharmaceuticals Corporation is recalling 792 cartons of Promacta (eltrombopag olamine) 12.5 mg for Oral Suspension. The recall is being conducted due to possible cross-contamination with peanut flour. The affected product is a prescription-only medication manufactured by Halo Pharmaceuticals, Inc. and distributed by Novartis Pharmaceuticals Corporation.

The recall covers specific lots: 8H57901589 (Exp. 09/2020), 9H57900189 (Exp. 12/2020), and 9H57900289 (Exp. 12/2020). The product was distributed nationwide in the United States. The FDA has classified this recall as Class I, indicating a reasonable probability that use of or exposure to the violative product may cause serious adverse health consequences or death.

Patients and healthcare providers should stop using the affected lots of Promacta and contact their healthcare provider for guidance. Consumers should check their medication packaging for the lot numbers and expiration dates listed above to determine if they are affected.

The recalled product

Product
PROMACTA (ELTROMBOPAG OLAMINE)
Brand
PROMACTA
Affected units
792

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (4)

  • Lot #: 8H57901589
  • Exp. 09/2020
  • 9H57900189 and 9H57900289
  • Exp. 12/2020.

Distribution

Distributed nationwide across the United States.